Investigators accessed longitudinal human data from ebola virus vaccination for signals of efficacy against the Bundibugyo species now surging in the Democratic Republic of Congo.
|Articles|March 14, 2020
The ID Pipeline: FDA Activity From the Week of March 8, 2020
Author(s)Contagion® Editorial Staff
Here is a look at infectious disease-related US Food and Drug Administration (FDA) news from the week of March 8, 2020.
Advertisement
Here is a look at infectious disease-related US Food and Drug Administration (FDA) news from the week of March 8, 2020.
FDA Issues Emergency Use Authoriszation for Cobas SARS-CoV-2 Test
The US Food and Drug Administration (FDA) has granted Emergency Use Authorization for the cobas SARS-CoV-2 test. The test, produced by Roche, is used to detect SARS-CoV-2 in oropharyngeal and nasopharyngeal swab samples.
In light of the urgent medical need for testing, it is noteworthy that the test can be run on existing automated cobas 6800 and cobas 8800 analyzer systems which are available throughout the United States.
“Providing quality, high-volume testing capabilities will allow us to respond effectively to what the World Health Organization has characterized as a pandemic,” Thomas Schinecker, CEO of Roche Diagnostics, said in a press release.
This is one of
Read the full article
Paratek Submits pre-Emergency Use Authorization Application to FDA for Omadacycline
Paratek Pharmaceuticals has submitted a pre-Emergency Use Authorization application for omadacyline.
If the authorization is granted, the FDA could allow for the use of the antibiotics during a declared emergency for treatment and prophylaxis of pulmonary anthrax in a health emergency.
The authorization request was submitted by the Biomedical Advanced Research and Development Authority (BARDA) as part of a public-private partnership between Paratek and BARDA.
Read the full press release
Advertisement
Related to this article
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.